Viatris will pay up to $335 million to settle opioid-related claims. Settlement payments will support opioid treatment and related efforts. Viatris denies wrongdoing, citing small presence in U.S ...

Viatris has agreed to a settlement in which it will pay up to $335 million to resolve opioid-related claims to state and local governments, the Pittsburgh-based generics specialist said on Monday ...

Viatris to pay up to $335 million over nine years to settle opioid claims nationwide. The company has accrued $270 million for potential resolution, noted in its 2024 10-K filing. Pelosi’s ...

Viatris has made a play to expand its branded medicines business by licensing two late-stage drugs from Idorsia – for acute myocardial infarction (AMI) and systemic lupus erythematosus (SLE ...

In this article, we are going to take a look at where Viatris Inc. (NASDAQ:VTRS) stands against other best weight loss drug ...

Viatris to Pay up to $335 Million to Resolve Opioid-Related Claims (Reuters) -Viatris said on Monday it would pay up to a maximum of $335 million over nine years as part of a nationwide settlement ...

With a market cap of $14.8 billion, Viatris Inc. (VTRS) is a global pharmaceutical company formed in 2020 through the merger of Mylan and Upjohn, a former Pfizer division. Headquartered in ...

PITTSBURGH, April 7, 2025 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS) (the "Company") today announced it has reached a nationwide settlement framework to resolve opioid-related claims by states ...

Viatris (VTRS, Financials) will pay up to $335 million in annual installments over nine years to settle opioid-related claims from U.S. states, local governments, and tribal entities, the company ...